Rivaroxaban

BreastfeedingPediatric
  • TRADE NAME: Xarelto (Janssen)
  • INDICATIONS: Prevention of venous thromboembolism in patients undergoing knee or hip replacement surgery; treatment of deep vein thrombosis and pulmonary embolism
  • CLASS: Anticoagulant, Direct factor Xa inhibitor
  • HALF-LIFE: 5–9 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Anticoagulants, Aspirin, Atazanavir, Atorvastatin, Carbamazepine, Clarithromycin, Clopidogrel, Combined P-glycoprotein and strong CYP3A4 inhibitors and inducers, Conivaptan, Dabigatran, Darunavir, Delavirdine, Diclofenac, Efavirenz, Enoxaparin, Erythromycin, Fosamprenavir, HIV protease inhibitors, Indinavir, Itraconazole, Ketoconazole, Ketorolac, Lapatinib, Lopinavir, Nelfinavir, Phenobarbital, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Tipranavir, Voriconazole

PREGNANCY CATEGORY: C

Contra-indicated in patients with active pathological bleeding.

PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS and SPINAL/EPIDURAL HEMATOMA


See full prescribing information for complete boxed warning.

Our database has 75 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 04/24/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top